BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16316300)

  • 1. Pharmacogenetics of colorectal cancer.
    Marsh S
    Expert Opin Pharmacother; 2005 Dec; 6(15):2607-16. PubMed ID: 16316300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics in colorectal cancer: a systematic review.
    Funke S; Brenner H; Chang-Claude J
    Pharmacogenomics; 2008 Aug; 9(8):1079-99. PubMed ID: 18681783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of pharmacogenetics in chemotherapy of colorectal cancers].
    Ceppa F; Fontan E; Cremades S; Bihannic R; Bousquet A; Beauvillain L; Burnat P
    Rev Med Interne; 2007 Sep; 28(9):594-602. PubMed ID: 17624636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics of colorectal cancer prevention and treatment.
    Nguyen H; Tran A; Lipkin S; Fruehauf JP
    Cancer Invest; 2006 Oct; 24(6):630-9. PubMed ID: 16982469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic aspects in treatment of colorectal cancer--an update.
    Stoehlmacher J; Goekkurt E; Lenz HJ
    Pharmacogenomics; 2003 Nov; 4(6):767-77. PubMed ID: 14596640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.
    Moradi-Marjaneh R; Khazaei M; Seifi S; Hassanian SM; Ferns GA; Avan A
    Curr Pharm Des; 2018; 24(23):2710-2718. PubMed ID: 30051785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualizing chemotherapeutic treatment of colorectal cancer.
    Crews KR
    Am J Health Syst Pharm; 2006 May; 63(9 Suppl 2):S12-7. PubMed ID: 16641252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
    Cortejoso L; López-Fernández LA
    Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer: pharmacogenetics support for the correct drug prescription.
    Olivera G; Sendra L; Herrero MJ; Puig C; Aliño SF
    Pharmacogenomics; 2019 Jul; 20(10):741-763. PubMed ID: 31368847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of genetic testing in the management of colorectal cancer.
    Stoehlmacher J; Lenz HJ
    Am J Pharmacogenomics; 2003; 3(2):73-88. PubMed ID: 12749725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
    Milano G
    Rev Prat; 2008 May; 58(10):1056-9. PubMed ID: 18652401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics in chemotherapy of colorectal cancer.
    Henriette Tanja L; Guchelaar HJ; Gelderblom H
    Best Pract Res Clin Gastroenterol; 2009; 23(2):257-73. PubMed ID: 19414151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of pharmacogenomics on gastrointestinal cancer therapy.
    Seufferlein T; Boehm BO
    Pharmacogenomics; 2002 Sep; 3(5):625-33. PubMed ID: 12223048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.
    Bandrés E; Zárate R; Ramirez N; Abajo A; Bitarte N; Garíia-Foncillas J
    World J Gastroenterol; 2007 Nov; 13(44):5888-901. PubMed ID: 17990354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.
    Braun MS; Quirke P; Seymour MT
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):489-501. PubMed ID: 17428170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.
    Panczyk M
    World J Gastroenterol; 2014 Aug; 20(29):9775-827. PubMed ID: 25110414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.
    Schirripa M; Procaccio L; Lonardi S; Loupakis F
    Pharmacogenomics; 2017 Feb; 18(3):197-200. PubMed ID: 28112993
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
    Tan BR; McLeod HL
    Semin Oncol; 2005 Feb; 32(1):113-9. PubMed ID: 15726513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.